After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/3/2026

1. SNOW
2. AVGO
3. RARE
4. HPE
5. FIVE
6. SPY
7. VRTS
8. NTAP
9. NTSK
10. OLLI

Go back to After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust

Truist Securities Downgrades IGM Biosciences (IGMS) to Hold

October 1, 2024 6:52 AM EDT

Truist Securities analyst Asthika Goonewardene downgraded IGM Biosciences (NASDAQ: IGMS) from Buy to Hold with a price target of $12.00 (from $24.00).

The analyst comments "What started as a side-hustle is now a full scale pivot - IGMS is now solely focused on autoimmune... More

IGM Biosciences (IGMS) PT Lowered to $17 at RBC Capital

October 1, 2024 6:32 AM EDT

RBC Capital analyst Brian Abrahams lowered the price target on IGM Biosciences (NASDAQ: IGMS) to $17.00 (from $20.00) while maintaining a Outperform rating.

The analyst comments "While discontinuation of aplitabart is disappointing, evolution into a pure-play autoimmune company with T-cell engagers should streamline... More

Jefferies Reiterates Buy Rating on IGM Biosciences (IGMS)

October 1, 2024 6:16 AM EDT

Jefferies analyst Roger Song reiterated a Buy rating and $48.00 price target on IGM Biosciences (NASDAQ: IGMS)

The analyst comments "We caught up with mgmt. Co has focused on autoimmune franchise for a while, along with partner Sanofi's recent strategic shift, so... More

Morgan Stanley Reiterates Equalweight Rating on IGM Biosciences (IGMS)

October 1, 2024 6:09 AM EDT

Morgan Stanley analyst Michael Ulz reiterated an Equalweight rating and $12.00 price target on IGM Biosciences (NASDAQ: IGMS)

The analyst comments "IGM announced multiple updates, including a pipeline reprioritization focused on T cell engagers for autoimmune diseases and discontinuation of oncology development,... More